US pharmaceutical company Par Health Inc announced on Friday the launch of its generic version of Merck's Janumet XR (sitagliptin and metformin HCl extended-release) tablets for oral use, following final approval from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application.
Par Health's sitagliptin metformin XR is the first and currently the only FDA-approved generic of Janumet XR available in the United States. According to IQVIA data, Janumet XR had estimated annual US sales of approximately USD269.9m for the 12 months ended May 2026.
Janumet XR is a registered trademark of Merck Sharp & Dohme LLC.
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension